Rh2 further significantly inhibited the proliferation of primary AML cells treated with sTRAIL or zA4 (Fig. 7f, g), which induced the expression of the TRAIL-related receptors DR4, DR5, and DcR1 (Fig. 7h). This evidence concerns the gene TNFRSF10C and acute myeloid leukemia.